About Event
Date & Time: October 6 – October 8, 2026, Milan, Italy
Rezon Bio will be attending CPHI Worldwide 2026, bringing together pharmaceutical and life sciences leaders from around the world.
Visit us at Booth #12J42 to discuss how we can support your biologics development and manufacturing programs.
Join The Panels with Adriana
Panel 1
Speaker: Adriana Kiędzierska-Mencfel, CEO
Title: Pharma’s Structural Shift: What’s Reshaping Global Priorities
Date & Time: October 6, 10:57-11:49, Auditorium – Stella Polare
Information:
The pharmaceutical industry is being reshaped by three major forces: economic pressures from pricing reforms, geopolitical shifts as countries prioritize medicine security, and rapid scientific advances in new therapies and digital tools. These changes are forcing companies to rethink long-standing approaches to supply chains, investment, and market access. This panel explores how leaders are responding, where innovation meets infrastructure limits, where policy goals clash with business realities, and how regional differences are creating new competitive dynamics.
You can find more information here: https://www.cphi.com/europe/leadership-summit/
Panel 2
Title: The CEO’s Weekly Challenge: Capacity or Indication
Date & Time: October 7, 15:15 – 16:00, the AI & Tech stage
Information:
Every CDMO CEO faces the same unresolved question: build broad, flexible capacity and hope the demand shows up, or bet on a specific therapeutic indication and specialise around it. Get it wrong, and you’re left with either an empty cleanroom or a therapeutic class that stalls and takes the business with it. This panel brings together three CDMO CEOs – spanning delivery platforms, sterile formulation, and biosimilar manufacturing – for a candid conversation about how they actually make that call, week after week. Expect an honest look at capacity risk versus indication risk, when it makes sense to build a capability versus buy it versus partner for it, and how far out CEOs are genuinely forecasting demand before they commit years of capital.
Join The Panel with Hubert
Speaker: Hubert Scholze, CBO
Title: CDMO Strategic Inflection Point: From Capacity Provider to Innovation Architect
Date & Time: October 8, 10:30-11:15, Manufacturing 5.0: Hall 10 – 10K69
Information:
The CDMO industry has reached a strategic inflection point where competitive advantage no longer comes from simply offering capacity or geographic reach. Success is now defined by three converging forces: selective partnership models, execution excellence in complex modalities, and digital manufacturing readiness. This panel brings together CDMO leaders to discuss how they’re repositioning their organizations as innovation architects who co-create manufacturing solutions with pharma partners.
Join our Scientific Presentation
Speaker: Fenil Patel, Director of External Tech Transfer
Title: Resilience Is the New Capacity: Building Manufacturing Advantage Through Strategic CDMO Partnerships
Date & Time: October 7, 14:15-14:40, Next-Gen Bio, Hall 12, 12F49.
Abstract:
As biologics programs advance toward commercialization, success increasingly depends on the ability to combine quality, price competitiveness, technological fit, and product-oriented partnerships with regulatory alignment. Manufacturing advantage is no longer defined by capacity alone. The companies best positioned for commercial success are those that combine quality and reliability (Baseline), competitive and scalable operations (Differentiator), technological fit and regulatory execution scientific excellence (Accelerant), and product-oriented partnerships (Confidence) to create resilient manufacturing networks capable of supporting the full product lifecycle.
This session explores how biopharma and biotech companies can create manufacturing advantage through the right CDMO partnerships and resilient supply strategies, including dual-site and network sourcing, to mitigate risk, maintain supply continuity and accelerate the path to commercialization.
Connect with our team
